Oncology & Hematology

Our ultimate vision is to prevent and provide cures for cancer in all its forms. Recognizing that no single intervention can achieve this comprehensive goal, we strive to deeply understand the disease, its complexities, and its impact on patients.

We are proud to have the broadest and most diverse pipeline in oncology, with more than 20 immunotherapy molecules currently in development. Since 2011, we have introduced 18 oncology medicines. Our efforts are united by a commitment to exploring therapeutic combinations and pursuing personalized medicines.

Reflecting our pharma strategy, we aim to bolster end-to-end investment in key disease areas (lung cancer, breast cancer, and malignant haematological conditions), while continually seeking transformative medicines in other areas. This integrated approach ensures that we address the full spectrum of patient needs, from prevention and diagnosis to treatment and beyond.

Partnering opportunities we are looking for:

Tumor types

• Breast
• Lung
• Malignant haematology (including multiple myeloma (MM), lymphoma, acute myeloid leukemia (AML))
• Transformative therapies in other indications - notably including colorectal cancer (CRC), prostate, bladder

Pathways/modalities

• Oncogenic drivers
• Cancer cell dependencies
• Antibody Drug Conjugates (ADCs)
• Cancer immunotherapy - including TCEs, bispecifics, innate and stromal cell
• Allogeneic cell therapies

Example partnerships

Adaptive Biotechnologies – Partnering to bring neoantigen-directed T-cell therapies to the treatment of cancer

BioNTech – Collaboration to develop personalized cancer vaccines

KSQ Therapeutics – Collaboration on developing and commercializing KSQ-4279, a potent and selective small molecule inhibitor of USP1, a protein that regulates DNA damage response (DDR).

MediLink Therapeutics – Collaboration license agreement to develop next generation antibody drug conjugate candidate targeting c-Mesenchymal epithelial transition factor against solid tumors.

Regor Pharmaceuticals – Acquisition of Regor’s next-generation CDK inhibitors for the treatment of breast cancer. .

Poseida Therapeutics – Acquisition to augment our efforts to bring transformative medicines to patients across Oncology, Immunology and Neurology. .

Your dedicated partnering leads in Oncology and Hematology

Patrick Schleck, Head of Oncology and Hematology, Pharma Partnering

Zineb El Fajoui, Search & Evaluation Lead, Oncology and Hematology, Pharma Partnering